In addition, Todd M.P. et al. demonstrated that the combination of a PI3K/mTOR and a MAPK inhibitor can enhance anti-proliferative effects against CRC cell lines [40] and Wang H. et al. reported that targeting mTOR suppresses colon cancer growth [41], which suggested that mTOR and MAPK could be therapeutic targets for subtype c2. This evidence concerns the gene PIK3CA and malignant colon neoplasm.